Drug Profile
LL 067
Alternative Names: LL-067Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Capella Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Brain metastases
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for preclinical development in Brain metastases in USA
- 06 Jan 2016 Preclinical trials in Brain metastases in USA (unspecified route)
- 06 Jan 2016 Pharmacodynamics data from a preclinical study in brain metastases released by Capella Therapeutics